GENELUX-Final-Logo-Notagline.png
Genelux Corporation to Participate in Fireside Chat at the Guggenheim Inaugural Healthcare Innovation Conference
November 06, 2024 16:01 ET | Genelux Corporation
WESTLAKE VILLAGE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO...
Image for illustrative purposes only and does not represent actual data from the Termeer Center or MGH.
Sonrai Accelerates Cancer Therapeutics Research with Advanced Analytics
November 06, 2024 09:00 ET | Sonrai Analytics Ltd
BELFAST, Northern Ireland, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Sonrai Analytics (Sonrai), an AI precision medicine company providing advanced analytics to advance therapeutic development, is working...
sns insider pvt ltd.png
Global Molecular Modeling Market to Hit USD 19.47 Billion by 2032, Driven by Demand for Drug Discovery Innovation and Advanced Computational Tools | Research by SNS Insider
November 06, 2024 08:22 ET | SNS Insider pvt ltd
Austin, Nov. 06, 2024 (GLOBE NEWSWIRE) -- “According to SNS Insider, The Molecular Modeling Market Size, valued at USD 6.40 billion in 2023, is projected to reach USD 19.47 billion by 2032, growing...
Madrigal logo.jpg
Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences
November 06, 2024 08:00 ET | Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in fireside chats at three upcoming investor...
barinthuslogo.jpg
Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results
November 06, 2024 08:00 ET | Barinthus Biotherapeutics
Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results
Quell TX Logo (RGB)-100.jpg
Quell Therapeutics to Participate at Upcoming Healthcare Investor Conferences
November 06, 2024 07:30 ET | Quell TX
London, UK – November 6, 2024 – Quell Therapeutics Ltd (“Quell”), a world leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system,...
ROI-Influencers_Health-Care-2024_Sector-Stars_Saadi-Dr.-Ryan-1024x667
Tevogen Bio CEO Dr. Ryan Saadi Expresses Gratitude for Prestigious ROI-NJ Recognition, Highlighting Company’s Novel Business Model as Key to Sustainable Success through Patient Affordability
November 05, 2024 16:43 ET | Tevogen Bio Inc
Tevogen Bio is a fully functional biotech, with investor-valued assets over $10 billion achieved with under $40 million in spending.Approximately 78% of Tevogen Bio's common stock is held by company...
nouscom logo.png
Nouscom’s Off-the-Shelf Neoantigen Immunotherapy, NOUS-209, Continues to Elicit Potent and Durable Immune Responses in Lynch Syndrome Carriers Highlighting its Potential to ‘Intercept’ Cancer
November 05, 2024 09:01 ET | Nouscom Srl
Lynch Syndrome (LS) is a common hereditary condition (affecting one in 300) conferring a high risk of developing colorectal, gastric, endometrial and other cancers NOUS-209 monotherapy is well...
Prognomiq_Logo_RGB.jpg
PrognomiQ Announces $34 Million Series D Financing to Advance Development of Early Detection Test for Lung Cancer with Multi-omics Platform
November 05, 2024 09:00 ET | PrognomiQ
PrognomiQ Announces $34 Million Series D Financing to Advance Development of Early Detection Test for Lung Cancer with Multi-omics Platform
outpace logo.png
Outpace Bio to present new data on programmed CAR T cell candidate OPB-101 at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 05, 2024 09:00 ET | Outpace Bio
Outpace Bio at SITC 2024: AI-powered OPB-101 CAR T cells show lasting functional persistence, enhanced anti-tumor activity, & stem central memory phenotype